Edison Pharmaceuticals Announces Results Of EPI-A0001 Phase 2A Double Blind Placebo Controlled 28-Day Clinical Trial In The Mitochondrial Disease

Main Category: Genetics
Also Included In: Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 11 Jun 2011 – 0:00 PDT
email icon email to a friend   printer icon printer friendly   write icon opinions  

Edison Pharmaceuticals, Inc. announced preliminary results obtained on a 28-day phase 2A clinical trial in Friedreich’s ataxia. While the primary endpoint of glucose disposition index (a measure of glucose handling by the body) did not show statistically significant improvement, EPI-A0001 did significantly improve neurological function as assessed by the Friedreich’s Ataxia Rating Scale (FARS). This double-blind placebo-controlled trial consisted of three arms: placebo, low dose, and high dose EPI-A0001. The improvement in the FARS was statistically significant in both the high and low dose groups in comparison to placebo. There were no differences in the rates of drug-related adverse events between the placebo group and each of the drug-treated groups.

EPI-A0001 has received orphan designation from FDA. On February 25, 2010, the FDA granted Fast Track designation to EPI-A0001 for Friedreich’s ataxia.

The results of this study are preliminary. Additional clinical trials will be required to determine the safety and effectiveness of EPI-A0001 for the proposed indication.

About Friedreich’s Ataxia

Friedreich’s ataxia is an autosomal nDNA inherited mitochondrial disease, affecting an estimated 50,000 individuals worldwide. Friedreich’s ataxia is caused by a defect in the gene frataxin, which is a 210 amino acid protein that participates in iron-sulfur (Fe-S) cluster protein assembly. As the majority of these Fe-S cluster proteins are localized to the respiratory chain in the mitochondria, patients with Friedreich’s ataxia present with “energy failure” symptoms including heart failure, ataxia, diabetes, and visual and hearing deficiencies. Friedreich’s ataxia is a highly debilitating and life-shortening disease. There are no FDA-approved drugs for Friedreich’s ataxia.

Source: Edison Pharmaceuticals, Inc


Please rate this article:
(Hover over the stars
then click to rate)
Patient / Public:orHealth Professional:

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

twitter icon  Follow us on Twitter
news icon  Genetics headlines
email icon  email to a friend
printer icon  printer friendly version
newsletter icon  weekly newsletter
star icon  personalize your news

back to top - icon  back to top


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Back to topBack to front pageList of All Medical Articles

MediLexicon International Ltd Logo

Privacy Policy | Terms and Conditions


MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.


Other news you may like:

  1. Marinus Pharmaceuticals Announces Commencement Of Phase 2 Trial Of Ganaxolone For The Treatment Of Posttraumatic Stress Disorder
  2. Amira Pharmaceuticals Announces Completion Of Phase 1 Clinical Study For AM152, A Novel LPA1 Receptor Antagonist
  3. Oncolytics Biotech® Inc. Announces Positive Data From Translational Clinical Trial Investigating REOLYSIN®
  4. Wake Forest Baptist Medical Center And Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial Of CPI-613 In Acute Myeloid Leukemia
  5. ACT Files European Clinical Trial Application For Phase 1/2 Study Using Embryonic Stem Cells To Treat Macular Degeneration
  6. Merrimack Pharmaceuticals Announces That Recruitment Is Open In A Phase 1 Combination Study Of MM-111 With Multiple Treatment Regimens

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>